This paper reports the anti-infective treatment strategy analysis of a patient who underwent endoscopic endonasal transsphenoidal pituitary tumor resection and subsequently developed intracranial infections caused by vancomycin-resistant Enterococcus faecium and carbapenem-resistant Pseudomonas putida. In accordance with the patient's pathophysiological characteristics, cerebrospinal fluid bacterial culture results and the pharmacokinetic/pharmacodynamic profile of the drugs, clinical pharmacists and doctors collaborated and formulated individualized treatment protocols as follows: contezolid was administered orally for vancomycin-resistant Enterococcus faecium, colistimethate sodium combine with gentamicin were injected intrathecally for carbapenem-resistant Pseudomonas putida. After treatment, the patient's body temperature returned to normal, the routine and biochemical tests of cerebrospinal fluid normalized, her neck resistance became negative, and no severe adverse drug reactions occurred, the patient was discharged smoothly. This case provides valuable clinical experience for the individualized management of complex intracranial infections caused by multidrug-resistant organisms.

1.中国医师协会神经外科分会神经内镜专家委员会, 中国医师协会内镜医师分会神经内镜专业委员会, 中国医师协会神经修复学专业委员会. 内镜经鼻颅底外科手术后中枢神经系统感染诊治中国专家共识[J]. 中华神经外科杂志, 2022, 38(3): 220-226. DOI: 10.3760/cma.j.cn112050-20211209-00578.

2.中国医师协会神经外科医师分会神经重症专家委员会, 北京医学会神经外科学分会神经外科危重症学组. 神经外科中枢神经系统感染诊治中国专家共识（2021版）[J]. 中华神经外科杂志, 2021, 37(1): 2-15. DOI: 10.3760/cma.j.cn112050-20200831-00480.

3.郭燕, 胡付品, 朱德妹, 等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2024, 24(6): 627-637. [Guo Y, Hu FP, Zhu DM, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program, 2023[J]. Chinese Journal of Infection and Chemotherapy, 2024, 24(6): 627-637.] DOI: 10.16718/j.1009-7708.2024.06.001.

4.陈万贞, 李轶, 尹海庆, 等. 河南144所医院2019—2020年恶臭假单胞菌感染临床特点及药敏分析[J]. 中国合理用药探索, 2024, 21(10): 79-84. [Chen WZ, Li Y, Yin HQ, et al. Clinical characteristics and susceptibility analysis of Pseudomonas putida infection in 144 Henan hospitals during 2019 and 2020[J]. Chinses Journal of Rational Drug Use, 2024, 21(10): 79-84.] DOI: 10.3969/j.issn.2096-3327.2024.10.012.

5.Mokhtar MN, Azaharuddin I, Abdullah FH, et al. A rare case of Pseudomonas putida ventriculitis in intensive care unit: a case report[J]. Front Med (Lausanne), 2022, 9: 1058121. DOI: 10.3389/fmed.2022.1058121.

6.Baykal H, Çelik D, Ülger AF, et al. Clinical features, risk factors, and antimicrobial resistance of Pseudomonas putida isolates[J]. Medicine (Baltimore), 2022, 101(48): e32145. DOI: 10.1097/MD.0000000000032145.

7.Tan G, Xi Y, Yuan P, et al. Risk factors and antimicrobial resistance profiles of Pseudomonas putida infection in Central China, 2010-2017[J]. Medicine (Baltimore), 2019, 98(44): e17812. DOI: 10.1097/MD.0000000000017812.

8.Mareković I, Markanović M, Lešin J, et al. Vancomycin-resistant Enterococci: current understandings of resistance in relation to transmission and preventive strategies[J]. Pathogens, 2024, 13(11): 966. DOI: 10.3390/pathogens13110966.

9.Sy CL, Chen PY, Cheng CW, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms[J]. J Microbiol Immunol Infect, 2022, 55(3): 359-386. DOI: 10.1016/j.jmii.2022.02.001.

10.临床常用四环素类药物合理应用多学科专家共识编写组, 中华预防医学会医院感染控制分会, 中国药理学会临床药理分会. 临床常用四环素类药物合理应用多学科专家共识[J]. 中华医学杂志, 2023, 103(30): 2281-2296. DOI: 10.3760/cma.j.cn112137-20230313-00389.

11.Food and Drug Adminsitration. FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning[EB/OL]. (2018-05-03) [2026-03-10]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline.

12.Lee BJ, Vu BN, Seddon AN, et al. Treatment considerations for CNS infections caused by vancomycin-resistant Enterococcus faecium: a focused review of linezolid and daptomycin[J]. Ann Pharmacother, 2020, 54(12): 1243-1251. DOI: 10.1177/10600 28020932513.

13.Nau R, Blei C, Eiffert H. Intrathecal antibacterial and antifungal therapies[J]. Clin Microbiol Rev, 2020, 33(3): e00190-19. DOI: 10.1128/CMR.00190-19.

14.Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice guidelines for healthcare-associated ventriculitis and meningitis[J]. Clin Infect Dis, 2017, 64(6): e34-e65. DOI: 10.1093/cid/ciw861.

15.Gilbert DN, Chambers HF, Eliopoulos GM, et al. The Sanford guide to antimicrobial therapy, 53rd eds[M]. Sperryville, VA: Antimicrobial Therapy Inc., 2023: 9.

16.中国防痨协会, 《中国防痨杂志》编辑委员会, 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 等. 康替唑胺治疗结核病专家共识[J]. 中国防痨杂志, 2025, 47(2): 123-129. DOI: 10.19982/j.issn.1000-6621.20240480.

17.Wright A, Deane-Alder K, Marschall E, et al. Characterization of the core ribosomal binding region for the oxazolidone family of antibiotics using Cryo-EM[J]. ACS Pharmacol Transl Sci, 2020, 3(3): 425-432. DOI: 10.1021/acsptsci.0c00041.

18.Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile[J]. J Med Chem, 2014, 57(11): 4487-4497. DOI: 10.1021/jm401931e.

19.Yang W, Li X, Chen J, et al. Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus[J]. J Antimicrob Chemother, 2024, 79(12): 3132-3141. DOI: 10.1093/jac/dkae331.

20.Zhao X, Huang H, Yuan H, et al. A phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections[J]. J Antimicrob Chemother, 2022, 77(6): 1762-1769. DOI: 10.1093/jac/dkac073.

21.Wang J, Xue Y, Nie W, et al. Safety and tolerability of contezolid versus linezolid for short-term treatment of rifampicin-resistant pulmonary tuberculosis: a randomized controlled study[J]. Infect Drug Resist, 2025, 18: 3307-3315. DOI: 10.2147/IDR.S516991.

22.Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: a case report[J]. Int J Antimicrob Agents, 2023, 62(2): 106875. DOI: 10.1016/j.ijantimicag.2023.106875.

23.Wang S, Cai C, Shen Y, et al. In vitro activity of contezolid against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and strains with linezolid resistance genes from China[J]. Front Microbiol, 2021, 12: 729900. DOI: 10.3389/fmicb.2021.729900.

24.Xu Z, Zhang J, Guan T, et al. Case report: successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid[J]. Front Med (Lausanne), 2023, 10: 1224179. DOI: 10.3389/fmed.2023.1224179.

25.Tamma PD, Aitken SL, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) [J]. Clin Infect Dis, 2022, 75(2): 187-212. DOI: 10.1093/cid/ciac268.

26.中国医药教育协会感染疾病专业委员会, 中华医学会呼吸病学分会, 中华医学会重症医学分会, 等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识[J]. 中华结核和呼吸杂志, 2021, 44(4): 292-310. DOI: 10.3760/cma.j.cn112147-20201109-01091.

27.Rajakani SG, Xavier BB, Sey A, et al. Insight into antibiotic synergy combinations for eliminating colistin heteroresistant klebsiella pneumoniae[J]. Genes (Basel), 2023, 14(7): 1426. DOI: 10.3390/genes14071426.

28.Ontong JC, Ozioma NF, Voravuthikunchai SP, et al. Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates[J]. PLoS One, 2021, 16(1): e0244673. DOI: 10.1371/journal.pone.0244673.